FDA to revise Novartis' Gilenya label to reflect brain infection risk

(Reuters) - The U.S. Food and Drug Administration said it will update the label of Novartis AG's multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news